Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Ovarian Neoplasms 1Mesothelioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 31Nivolumab 12Cyclophosphamide 10fludarabine 9aldesleukin 8atezolizumab 7durvalumab 6Magnetic Resonance Spectroscopy 6Trastuzumab 5Specimen Handling 5Paclitaxel 5Ipilimumab 5Docetaxel 5Biopsy 5fludarabine phosphate 4Radiotherapy 4Interleukin-2 4Gene Expression Profiling 4Carboplatin 4tisotumab vedotin 3cemiplimab 3aflibercept 3Polymerase Chain Reaction 3Immunoglobulin G 3Early Intervention, Educational 3Cisplatin 3Bevacizumab 3tremelimumab 2tislelizumab 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × bosutinib × Genitourinary × Clear all
NCT03023319 2022-06-14

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Augusta University

Phase 1 Completed
6 enrolled
GenitourinaryGynecologicOther solid neoplasmThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Mesothelioma, Ovarian Neoplasms, Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡